- Home
- SILV vs DVAX Comparison
SILV vs DVAX Comparison
Compare SILV & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILV
- DVAX
- Stock Information
- Founded
- SILV 2015
- DVAX 1996
- Country
- SILV Canada
- DVAX United States
- Employees
- SILV N/A
- DVAX N/A
- Industry
- SILV Industrial Machinery/Components
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- SILV Industrials
- DVAX Health Care
- Exchange
- SILV Nasdaq
- DVAX Nasdaq
- Market Cap
- SILV 1.2B
- DVAX 1.5B
- IPO Year
- SILV N/A
- DVAX 2004
- Fundamental
- Price
- SILV $10.29
- DVAX $10.92
- Analyst Decision
- SILV Buy
- DVAX Buy
- Analyst Count
- SILV 4
- DVAX 3
- Target Price
- SILV $9.75
- DVAX $23.67
- AVG Volume (30 Days)
- SILV 2.6M
- DVAX 1.6M
- Earning Date
- SILV 11-12-2024
- DVAX 10-31-2024
- Dividend Yield
- SILV N/A
- DVAX N/A
- EPS Growth
- SILV 33.28
- DVAX N/A
- EPS
- SILV 0.72
- DVAX 0.13
- Revenue
- SILV $261,535,000.00
- DVAX $249,694,000.00
- Revenue This Year
- SILV $3.90
- DVAX $23.66
- Revenue Next Year
- SILV N/A
- DVAX $19.46
- P/E Ratio
- SILV $14.32
- DVAX $85.06
- Revenue Growth
- SILV 59.97
- DVAX N/A
- 52 Week Low
- SILV $4.79
- DVAX $9.74
- 52 Week High
- SILV $10.72
- DVAX $15.15
- Technical
- Relative Strength Index (RSI)
- SILV 62.36
- DVAX 50.51
- Support Level
- SILV $9.90
- DVAX $10.12
- Resistance Level
- SILV $10.72
- DVAX $11.14
- Average True Range (ATR)
- SILV 0.39
- DVAX 0.33
- MACD
- SILV 0.03
- DVAX 0.01
- Stochastic Oscillator
- SILV 75.27
- DVAX 54.79
About SILV SilverCrest Metals Inc.
SilverCrest Metals Inc involves in the exploration, development, and extraction of silver and other precious metals. The company's properties include Las Chispas, Cruz de Mayo, El Picacho and other projects.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.